Understanding genetic variation and function is critical to the development of personalized medicine, a key goal of genomics. The Company's tools will provide information that could be used to improve drugs and therapies, customize diagnoses and treatment, and cure disease. Illumina intends to provide both products and services that utilize its proprietary technologies. The Company's first products, developed in partnership with PE Biosystems, will include disposable BeadArray cassettes, reagent kits for analyzing variation in genetic sequences, and instruments that automatically read data from the BeadArray cassettes. Illumina also plans to commercialize services for the analysis of genetic variation.
Revenues reflect an increase in government grants.
Higher loss reflects an increase in salaries and other personnel-related expenses. Market Guide offers more in-depth Company Research , Stock Screening , and Hottest Stocks and Industries on over 10,000 U.S. Equities. All Rights Reserved. Privacy Policy - Terms of Service Company information Copyright Market Guide . Some event data provided by StreetEvents .